Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215136 · ClinicalTrials.gov registry record · Phase 2
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
A Phase 2 study, sponsored by Matthew Galsky.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01215136: Clinical Trial Phase 2 study, sponsored by Matthew Galsky.
NCT01215136 is a Phase 2 study that was terminated before completion, run by Matthew Galsky. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01215136, a Phase 2 study, was terminated before completion, sponsored by Matthew Galsky.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
Primary Outcome
To evaluate clinical benefit rate (complete response, partial response, and stable disease) at 4 months from initiation of treatment.
Interventions
- DRUG Paclitaxel
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-12 |
| Est. Completion | 2018-04-24 |
| Phase | Phase 2 |
Why NCT01215136 stopped before completion
NCT01215136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT01215136 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01215136 about?
NCT01215136 is a clinical study titled "First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma". The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
What is the current status of trial NCT01215136?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2010-12. Estimated completion is 2018-04-24.
What interventions are being tested in trial NCT01215136?
The interventions under investigation include: Paclitaxel (DRUG), Everolimus (DRUG).
Who is sponsoring clinical trial NCT01215136?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01215136's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia